BioArctic has a strong financial position and a business model that means the company’s revenues and results are primarily based on milestone payments, royalty revenues, and co-promotion agreement revenues that the company has entered into. The company’s liquidity enables the continued development of its own less costly projects. All of BioArctic’s pharmaceutical areas, such as Alzheimer’s disease, Parkinson’s disease, and research within ALS and other neurodegenerative diseases, are areas that currently lack effective treatments and have a large market potential. The company’s ambition is to develop the medicines of the future that improve the quality of life for people with diseases of the central nervous system. The company’s cash position remains strong, which creates opportunities for a continued exciting development of BioArctic.
The board’s goal is to provide shareholders with a dividend that yields a good direct return and robust dividend growth over time. When determining the dividend, the company’s earnings development, cash flow, investment needs, and overall financial position should be considered. The dividend should be well-balanced with respect to the company’s objectives, scope, and risk